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Objective: The aim of this study was to evaluate the feasibility of using novel autoan-
tibody and cancer-related protein arrays to identify potential biomarkers for the early
detection of esophageal adenocarcinoma in serum.
Methods: Sera from 18 patients with esophageal adenocarcinoma and 14 with gastro-
esophageal reflux disease were added to microarrays designed to detect circulating
autoantibodies to 51 tumor-associated antigens. Sera from the same patients were
also added to a 53-plex assay for various cancer-related proteins. Cutoff values at 3
standard deviations above the mean expression of gastroesophageal reflux disease
were used as a boundary for positivity.
Results: Nine proteins and 11 autoantibodies were able to individually segregate at
least 1 esophageal adenocarcinoma sample from gastroesophageal reflux disease by
means of cutoff values. The most discriminative marker was Fas ligand in the protein
array, which was associated with 83.3% sensitivity and 100% specificity. The best
performing autoantibody, NY-ESO-1, detected 3 esophageal adenocarcinoma sam-
ples. When both of these markers were combined, a sensitivity of 88.9% and specific-
ity of 100% were attained.
Conclusions: Cancer-related protein and autoantibody arrays provide a technically
simple and rapid method of identifying potential biomarkers for the detection of
esophageal adenocarcinoma in serum. Furthermore, combining these platforms im-
proves the diagnostic power of either platform alone. Integrating technologies that
detect the expression of multiple proteins and autoantibodies in serum may provide
a noninvasive and accurate method of detecting early esophageal adenocarcinoma.
T
he incidence of esophageal adenocarcinoma (EAC) in the United States has
increased by 5-fold in the past 30 years, representing the most drastic rise of
any cancer.1 Epidemiologic data suggest that this rise may be due to similar
increases in the incidences of gastroesophageal reflux disease (GERD) and associated
Barrett esophagus, inasmuch as EAC is thought to follow ametaplasia–dysplasia–car-
cinoma sequence.2 In addition, esophageal cancer has a dismal 5-year survival of 10%
to 15% despite advances in medical and surgical therapy. This is most likely a result of
more than 50% of patients having incurable disease on first examination, emphasizing
the need for developing better methods of early detection.3
Current screening of patients with GERD who are at risk for EAC is limited to en-
doscopic surveillance, a method that requires sedation and is associated with high in-
terobserver variability and a possibility of esophageal perforation. A noninvasive and
inexpensive diagnostic tool that accurately detects EAC would allow for a broader
screening program, increased probability of early detection, and ultimately an im-
provement in the dismal survivals of patients with EAC. These requirements may
be fulfilled by technology that analyzes multiple biomarkers in serum.
The contents of tumor cells reach the blood to constitute part of the serum proteome
either through active secretion or after cellular damage. The presence of elevated
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tumor-related proteins in serum, such as cytokines, epithelial
cell markers, chemokines, growth factors, and angiogenic
factors, have been demonstrated to be an important repository
for experimental diagnostic tests in the detection of malig-
nancy.4-7 The fact that there are very few individually sensi-
tive cancer biomarkers underscores the need for multiple
marker panels to achieve higher diagnostic performance.
The Luminex system (Luminex Corp, Austin, Tex) is
based on laboratory multi-analyte profiling (LabMAP tech-
nology that uses up to 100 color-coded bead sets, each of
which can be conjugated with a different reactant. This ad-
vanced LabMAP biomarker technology is capable of analyz-
ing more than 100 different protein markers in an automated,
internally controlled assay. Recent reports have demonstrated
LabMAP technology’s superior performance in identifying
patients with early ovarian and breast cancer, stimulating
the potential to establish a clinically reliable tool for the diag-
nosis of cancer.8,9
In addition to secreted proteins, the host response to tu-
mor-associated antigens can potentially be exploited for the
early detection of EAC. Autoantibodies directed at tumor-
associated antigens are thought to reflect aberrant expression
and structural or functional changes in autologous intracellu-
lar proteins. A major advantage of analyzing these antibodies
is that their production represents a dramatic amplification,
allowing for the detection of circulating levels at earlier
stages of tumor growth. CellCorrect microarrays (CeMines,
Golden, Colo) take advantage of this biological phenomenon
by containing selective cancer-specific antigen panels that
interact with serum autoantibodies by reverse immunocap-
ture. We hypothesized that these autoantibody arrays in com-
bination with cancer-related protein profiling would provide
a technically simple and rapid method of identifying potential
serum biomarkers in EAC.
Methods
Patient Population
Sera from 18 patients with EAC (stage II, n 5 4; stage III, n 5 9;
stage IV, n5 5) and 14 patients with GERD were obtained through
protocols approved by the Institutional Review Board at the Univer-
sity of Pittsburgh Medical Center. Age (mean 58.9 vs 58.2 years),
sex (all men), and smoking status (27.8% vs 28.6% nonsmokers)
were similar between the EAC and GERD groups, respectively.
Each sample was taken before anesthesia on the day of surgery
(esophagectomy for EAC, Nissen fundoplication for GERD) and
processed in an identical manner. Standard venipuncture technique200 The Journal of Thoracic and Cardiovascular Surgery c Juwas used to draw peripheral blood into 10-mL glass red top tubes,
and samples were left to stand for 30 minutes. Sera were then sepa-
rated by centrifugation, an aliquot was taken, and frozen at280C.
Freeze-thaw cycles were avoided.
Luminex Cancer-related Protein Profiling
Luminex LabMAP protein arrays were constructed with polystyrene
microspheres dyed with variable ratios of two spectrally different
fluorophores. These were used to create a family of 53 differentially
addressed bead sets, with each set conjugated to a capture antibody
specific for a unique soluble analyate. The 53 proteins that were
analyzed in this particular array included cytokines, chemokines, an-
giogenic factors, apoptotic proteins, proteases, cancer antigens, and
growth factors that have been demonstrated to be potential markers
in a variety of other cancers (Table 1).
Assay buffer (25 mL) was added to background and sample wells
in a 96-well microplate. Sera, 25 mL, from each EAC or GERD sam-
ple were added to appropriate wells in duplicate, followed by 25 mL
of the bead sets, and the mixture was shaken for 1 hour in the dark
with an orbital shaker. Wells were washed twice with 200 mL of
wash buffer and then incubated with 25 mL of detection antibody
for 30 minutes. After the addition of streptavidin–phycoerythrin so-
lution, washing, and resuspension, results were read on the Luminex
100 machine. In internal validation studies, our Luminex facility has
demonstrated low intra-assay (6.0%–8.2%) and interassay (5.7%–
8.4%) coefficients of variation for multiplexed LabMAP assays
using a variety of these biomarkers.
Dot plots were created to graphically express serum concentra-
tions (average intensity of duplicate runs) of each of the 53 analy-
ates. Cutoff values were established at 3 standard deviations above
the mean GERD concentration. The most discriminative marker
was chosen by assessing the associated sensitivities and specificities
of each individual protein using these cutoff boundaries.
Autoantibody Arrays
CellCorrect microarrays were created with 51 preprinted synthetic,
potentially immunogenic peptides that were selected on the basis
of cancer gene expression and immunome databases (Table 2).
These arrays were provided by CeMines free of charge for this anal-
ysis. Two microliters of each serum sample were diluted in binding
buffer (Tris-buffered saline containing blocking solution and 0.5
Tween-20) and incubated overnight with the peptide arrays at
4C. A secondary antibody (alkaline phosphatase conjugated anti-
human immunoglobulins A, M, and G; Chemicon AP120A, Milli-
pore, Billerica, Mass) was used to detect the immobilized serum
autoantibodies. Slides were imaged with a flatbed scanner and the
intensity of each spot was densitometrically assessed with software
from the manufacturer. Each sample was run twice on two separate
sets of arrays.
Similar to the Luminex analysis, dot plots were created to visual-
ize concentrations (average intensity of two independent runs) in
each EAC and GERD sample, and cutoff values were generated at
3 standarddeviations above themeanGERDvalue to establish a strict
boundary between a positive and negative test result. The most dis-
criminative autoantibody was determined by identifying the marker
associated with the highest sensitivity and specificity. The best per-
forming autoantibody and cancer-related proteinwere also combined
to assess whether their respective diagnostic powers were additive.ly 2008
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Biological groups Proteins
Cytokines IL-6, IL-8, IL-10, TNFa, TNFR I, TNFR II, IL-2R, sIL-6R, G-CSF
Chemokines MIP-1a, MIP-1b, MCP-1, Eotaxin, MIF
Growth/angiogenic factors EGFR, bFGF, HGF, VEGF, NGF, IGFBP-1
Cancer antigens CA 125, CA 15-3, CEA, AFP, CA 19-9, CA 72-4
Apoptotic proteins sFas, sFasL, FasL
Proteases Kallikrein 8, MMP-1,2,3,7,8,9,12,13
Adhesion molecules sICAM, sVCAM, sE-selectin
Other markers Aesothelin, tPAI-1, active PAI-1, ULBP-1, ULBP-2, ULBP-3, MICA, angiostatin, SCC
Adipokines Adiponectin, leptin, resistin
IL, Interleukin; TNF, tumor necrosis factor; TNFR I, tumor necrosis factor type I receptor; G-CSF, granulocyte-colony stimulating factor; MIP, macrophage
inflammatory protein; MIF, macrophage inhibitory factor; EGFR, epidermal growth factor receptor; bFGF, basic fibroblast growth factor; HGF, hepatocyte
growth factor; VEGF, vascular endothelial growth factor; NGF, nerve growth factor; IGFBP, insulin-like growth factor binding protein; CA, cancer antigen;
CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; FasL, Fas ligand;MMP, matrix metalloproteinase; ICAM, intercellular adhesion molecule; VCAM, vas-
cular cell adhesion molecule; PAI, plasminogen activator inhibitor; ULBP, UL16-binding protein;MICA, major histocompatibility complex class I-related chain
A; SCC, squamous cell carcinoma.G
TSResults
A total of 9 proteins were able to individually segregate at
least 1 EAC sample from the GERD group (Figure 1). Fas
ligand (FasL) was the marker associated with the highest
sensitivity (15/18 EAC; 83.3%) and specificity (14/14
GERD; 100%) using cutoff boundaries. In the CellCorrect
arrays, 11 autoantibodies were able to individually distin-
guish at least 1 EAC patient from GERD (Figure 2). The
best performing autoantibody was NY-ESO-1, which was
able to detect 3 EAC samples, 1 of which was unique to
those detected by FasL. Therefore, when combined, these
2 markers were associated with 88.9% sensitivity and
100% specificity.
Discussion
The incidence of EAC has been increasing at dramatic rates
over the past several decades. Additionally, the majority of
patients with EAC continue to have advanced, unresectable
disease on initial examination, resulting in dismal 5-year sur-
vivals that have only modestly improved since the 1970s.
These observations underscore the need for developing better
methods of early EAC detection. In the present study, we
hypothesized that a combination of platforms that analyze
cancer-related proteins as well as autoantibodies to tumor-
associated antigens in sera would provide a technically sim-
ple and rapid method of identifying potential biomarkers of
EAC.
TABLE 2. Discriminatory autoantibodies
Tumor-associated antigen Biological role
Adapter-related protein complex 1 gamma 2 subunit (AP1G2) Protein complex assembly, intracellular protein transport, endocytosis,
vesicle-mediated transport
Nascent-polypeptide-associated complex alpha (NACA) Transcription, protein biosynthesis, protein transport
Nischarin (NISCH) Intracellular signaling cascade, Rac protein signal transduction, actin
cytoskeleton organization and biogenesis, negative regulation of
cell migration
Serologically defined colon cancer antigen 3 (SDCCAG3) Protein trafficking, presentation of tumor necrosis factor receptor on
surface
UTP14, U3 small nucleolar ribonucleoprotein, homolog A
(UTP14A)
Ribosome biogenesis
Zinc finger protein 292 (ZNF292) Regulation of transcription, DNA-dependent
Nuclear factor related to kappa B binding protein (NFRKB) Transcription from RNA polymerase II promoter, inflammatory response
v-abl Abelson murine leukemia viral oncogene homolog 1
(ABL1)
Regulation of progression through cell cycle, S-phase–specific
transcription in mitotic cell cycle, mismatch repair, regulation of
transcription, DNA-dependent
Golgi autoantigen, golgin subfamily a,2 (GOLGA2) Protein binding
LIM and senescent cell antigen-like domains 1 (LIMS1) Cell–matrix adhesion, cell–cell adhesion, cell aging
Cancer/testis antigen B (NY-ESO-1) Biological process unknownThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 1 201
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TSFigure 1. Dot plots of discriminatory cancer-related proteins. Dot plots of 9 proteins that were able to individually
segregate at least 1 EAC sample from GERD. Black diamonds represent GERD and white squares represent EAC.
TNF-RI, Tumor necrosis factor receptor I; IL-2R, interleukin-2 receptor; IGFBP, insulin-like growth factor binding
protein; AFP, alpha-fetoprotein; MMP, matrix metalloproteinase; HGF, hepatocyte growth factor; FasL, Fas ligand;
PAI, plasminogen activator inhibitor.We analyzedmore than 100 proteins and autoantibodies in
sera taken from patients with EAC or GERD and found that
20 of these markers were able to individually distinguish at
least 1 cancer sample from the reflux cohort. As a preliminary
analysis, we combined the most discriminative protein
(FasL) and autoantibody (NY-ESO-1) and found that this
combination was associated with 88.9% sensitivity and
100% specificity. Indeed, FasL has been shown to be overex-
pressed in several types of cancers10-13 and likely represents
a mechanism whereby tumor cells induce apoptotic death
in Fas-expressing lymphocytes, thereby avoiding immune
destruction.14 Similarly, NY-ESO-1 is an antigen that has
been demonstrated to be overexpressed in a multitude of can-
cers.15 In fact, its specificity has drawn much attention to its
potential role in developing a cancer vaccine.202 The Journal of Thoracic and Cardiovascular Surgery c JulThe major limitation of this study is the relatively low
sample number. A more accurate measure of the sensitivity
and specificity of these markers will require prospective test-
ing with larger patient cohorts. The main focus of this article,
however, is the scientific and clinical appeal of biomarker ar-
ray systems rather than the validation of specific markers.
Moreover, these technologies allow the analysis of hundreds
of proteins within a few hours and, therefore, provide a fertile
ground for the identification of biomarkers that may have dis-
criminative capability in cancer. Furthermore, once potential
biomarkers have been validated, this technology would allow
for the integration of multiple markers into a single platform.
This concept is clinically relevant inasmuch as technical fea-
sibility and time requirement are important components of
determining the cost effectiveness of a screening or risky 2008
Kilic et al General Thoracic SurgeryFigure 2. Dot plots of discriminatory autoantibodies. Dot plots of 11 autoantibodies that were able to individually
segregate at least 1 EAC sample from GERD. Black diamonds represent GERD and white squares represent EAC.
AP1G2, Adapter-related protein complex 1 gamma 2 subunit; NACA, Nascent-polypeptide-associated complex al-
pha; NISCH, nischarin; SDCCAG3, serologically defined colon cancer antigen 3; UTP14A, U3 small nucleolar ribonu-
cleoprotein, homolog A; ZNF292, zinc finger protein 292; NFRKB, nuclear factor related to kappa B binding protein;
ABL1, v-abl abelson murine leukemia viral oncogene homolog 1; GOLGA2, golgi autoantigen, golgin subfamily a,2.G
TSstratification tool. Moreover, a subset analysis within patients
with EAC could be performed to identify those markers asso-
ciated with localized or advanced disease. This could reduce
the necessity for invasive staging procedures and could also
have a role in guiding adjuvant therapies.
In the setting of EAC, the development of a screening
tool for at-risk patients could be of significant value, espe-The Journal of Thocially in patients with Barrett esophagus with associated
high-grade dysplasia, in whom treatment guidelines remain
controversial. Those patients whose serum markers are sug-
gestive of underlying malignancy could undergo potentially
curative esophagectomy, whereas those patients without
these markers could be spared major surgery. This study
highlights potential platforms that could be of great valueracic and Cardiovascular Surgery c Volume 136, Number 1 203
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TSboth in identifying potential biomarkers and in developing
panels that are routinely used to assess cancer risk in the
clinical setting.
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